Immunohistochemical Analysis of Glucose Transporter-1 Expression and Angiogenic Index in Syndrome and Non-Syndrome Keratocystic Odontogenic Tumors

2015 ◽  
Vol 120 (2) ◽  
pp. e94
Author(s):  
RAFAELLA BASTOS LEITE ◽  
ROBERTA BARROSO CAVALCANTE ◽  
RENATO LUIZ MAIA NOGUEIRA ◽  
LÉLIA BATISTA DE SOUZA ◽  
LEÃO PEREIRA PINTO ◽  
...  
Keyword(s):  
Glucose Transporter ◽  
Immunohistochemical Analysis ◽  
Odontogenic Tumors ◽  
Glucose Transporter 1 ◽  
Keratocystic Odontogenic Tumors

scholarly journals Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma

2009 ◽  
Vol 16 (3) ◽  
pp. 919-928 ◽  
Author(s):  
Wiebke Fenske ◽  
Hans-Ullrich Völker ◽  
Patrick Adam ◽  
Stefanie Hahner ◽  
Sarah Johanssen ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Adrenocortical Carcinoma ◽  
Glucose Transporter ◽  
Disease Free Survival ◽  
Immunohistochemical Analysis ◽  
Radical Resection ◽  
Tissue Microarrays ◽  
Tissue Samples ◽  
Glucose Transporter 1 ◽  
Glut1 Expression

Owing to the rarity of adrenocortical carcinoma (ACC) no prognostic markers have been established beyond stage and resection status. Accelerated glycolysis is a characteristic feature of cancer cells and in a variety of tumour entities key factors in glucose metabolism like glucose transporter 1 and 3 (GLUT1 and -3), transketolase like-1 enzyme (TKTL1) and pyruvate kinase type M2 (M2-PK) are overexpressed and of prognostic value. Therefore, we investigated the role of these factors in ACC. Immunohistochemical analysis was performed on tissue microarrays of paraffin-embedded tissue samples from 167 ACCs, 15 adrenal adenomas and 4 normal adrenal glands. Expression was correlated with baseline parameters and clinical outcome. GLUT1 and -3 were expressed in 33 and 17% of ACC samples respectively, but in none of the benign tumours or normal adrenals glands. By contrast, TKTL1 and M2-PK were detectable in all benign tissues and the vast majority of ACCs. GLUT1 expression was strongly associated with prognosis in univariate and multivariate analysis (P<0.01), whereas GLUT3, TKTL1 and M2-PK did not correlate with clinical outcome. Patients with strong GLUT1 staining showed a considerably higher overall mortality (hazard ratio (HR) 6.34 (95% confidence interval 3.10–12.90) compared with patients with no GLUT1 staining. When analysing patients in their early stages and advanced disease separately, similar results were obtained. HR for survival was 5.31 (1.80–15.62) in patients with metatastic ACC and in patients after radical resection the HR for disease-free survival was 6.10 (2.16–16.94). In conclusion, GLUT1 is a highly promising stage-independent, prognostic marker in ACC.

scholarly journals Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Naoto Mukada ◽  
Masahiko Tosaka ◽  
Nozomi Matsumura ◽  
Rei Yamaguchi ◽  
Masanori Aihara ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Glucose Transporter ◽  
Immunohistochemical Analysis ◽  
Braf V600e ◽  
Beta Catenin ◽  
Hexokinase Ii ◽  
Glucose Transporter 1 ◽  
Positive Group ◽  
Glut 1 ◽  
Positive Rate

AbstractPapillary craniopharyngiomas are characterized by the BRAF V600E mutation. Enhancement of glucose metabolism may be involved in the downstream of the BRAF V600E mutation in many types of tumors. Glucose metabolism was investigated in craniopharyngioma using immunohistochemical analysis. The study included 29 cases of craniopharyngioma (18 adamantinomatous type [ACP], 11 papillary type [PCP]). Immunohistochemical analysis was performed with anti-glucose transporter-1 (GLUT-1), anti-hexokinase-II (HK-II), anti-BRAF V600E, and anti-beta-catenin antibodies. Expressions of GLUT-1 and HK-II were evaluated using a semiquantitative 4-tiered scale as 0, 1+, 2+, 3+, and divided into negative (0 or 1+) or positive (2+ or 3+) group. GLUT-1 expression level was significantly higher in PCPs than ACPs (0, 1+, 2+, 3+ = 2, 12, 4, 0 cases in ACP, respectively, 0, 1+, 2+, 3+ = 0, 2, 5, 4 in PCP, p = 0.001), and most PCPs were classified into positive group (positive rate, 22.2% [4/18] in ACP, 81.8% [9/11] in PCP; p = 0.003). HK-II expression was also conspicuous in PCPs (0, 1+, 2+, 3+ = 7, 9, 2, 0 cases in ACP, 0, 3, 3, 5 in PCP; p = 0.001), and most of them divided into positive group (positive rate, 11.1% [2/18] in ACP, 72.7% [8/11] in PCP; p = 0.001). Expression patterns of BRAF V600E and beta-catenin reflected the clinicopathological subtypes. Both GLUT-1 and HK-II expressions were prominent in PCP. Glucose metabolism might be more enhanced in PCP than ACP. PCP may use the glucose metabolic system downstream of the BRAF V600E mutant protein.

Comparative Immunohistochemical Analysis of Hmlh1, P63 and MDM-2 Expression in Syndrome and Non-Syndrome Keratocystic Odontogenic Tumors

2015 ◽  
Vol 120 (2) ◽  
pp. e105
Author(s):  
BÁRBARA VANESSA DE BRITO MONTEIRO ◽  
ROBERTA BARROSO CAVALCANTE ◽  
RENATO LUIZ MAIA NOGUEIRA ◽  
MÁRCIA CRISTINA DA COSTA MIGUEL ◽  
CASSIANO FRANCISCO WEEGE NONAKA ◽  
...  
Keyword(s):  
Immunohistochemical Analysis ◽  
Odontogenic Tumors ◽  
Keratocystic Odontogenic Tumors

scholarly journals Correlation Between Radiographic Area and Immunolocation of MMP-2 and MMP-9 in Unilocular Radiographic Lesions

2014 ◽  
Vol 25 (6) ◽  
pp. 466-471
Author(s):  
Rafaela Scariot ◽  
Lucas Caetano Uetanabaro ◽  
Melissa Rodrigues de Araujo ◽  
Joao Zielak ◽  
Allan Fernando Giovanini ◽  
...  
Keyword(s):  
Immunohistochemical Analysis ◽  
Biological Behavior ◽  
Odontogenic Tumors ◽  
Inverse Association ◽  
Bone Cysts ◽  
Maxillofacial Region ◽  
Pathological Conditions ◽  
Dentigerous Cysts ◽  
Ellipse Area ◽  
Keratocystic Odontogenic Tumors

Unilocular bone cysts are the most common entities affecting the maxillofacial region. The mechanism of proliferation and expansion remains unclear. Metalloproteinases (MMPs) are associated to diverse pathological conditions. The aim of the present study was to correlate the radiographic aspect (area) and the presence of MMP-2 and MMP-9 in dentigerous cysts, radicular cysts and keratocystic odontogenic tumors. The radiographic area of each lesion was calculated using the mathematical formula of the ellipse area. All specimens were subjected to immunohistochemical analysis for these enzymes. The average radiographic area was 284.17 mm2, 235.81 mm2 and 381.81 mm2, respectively. Statistical analyses revealed no association between the immunoreactivity of MMPs and radiographic area of the lesions in all pathologies studied, except for MMP-2 and radicular cysts, for which smaller lesions had increased immunostaining for this enzyme. The results demonstrate that quantities of MMP-2 and MMP-9 are especially involved with dentigerous and radicular cysts in expansion, whereas these enzymes seem to be related to the biological behavior of keratocystic odontogenic tumors, indicating invasion and cell proliferation. Moreover, there is an inverse association between MMP-2 and MMP-9 in keratocystic odontogenic tumors (p=0.03; rs=-0.660), indicating activity in different regions.

F-18 fluorodeoxyglucose uptake in leiomyomatous uterus

2007 ◽  
Vol 17 (1) ◽  
pp. 285-290 ◽  
Author(s):  
M. Shida ◽  
M. Murakami ◽  
H. Tsukada ◽  
Y. Ishiguro ◽  
K. Kikuchi ◽  
...  
Keyword(s):  
Uterine Leiomyoma ◽  
Glucose Transporter ◽  
Malignant Tumors ◽  
Premenopausal Women ◽  
Immunohistochemical Analysis ◽  
Whole Body ◽  
Common Disease ◽  
Glucose Transporter 1 ◽  
Positron Emission ◽  
Benign Leiomyoma

Leiomyomas of uterus are common disease in gynecology. It is important to differentiate leiomyoma from leiomyosarcoma at the decision of treatment methods, especially in the case of the conservative treatment for uterine leiomyoma. But the exact diagnosis of benign leiomyoma is often difficult due to the degeneration of myoma by imaging modalities including magnetic resonance imaging. Recently, whole-body positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG) has been used for a diagnosis of malignant tumors. There is a growing body of evidence for the use of FDG in differentiating malignant from benign disease. But optimal utilization in gynecology remains unclear. Our case represents increased uptake of FDG in myomatous uterus, which is pathologically confirmed benign leiomyoma by the hysterectomy. Immunohistochemical analysis of glucose transporter-1 showed positive in endometrial tissue and negative in leiomyoma. Our case indicates that myomatous uterus in premenopausal women shows the potential pitfall of a positive result of FDG-PET

scholarly journals GLUT3 expression in cystic change induced by hypoxia in pituitary adenomas

2018 ◽  
Vol 7 (12) ◽  
pp. 1518-1527
Author(s):  
Tao Mei ◽  
Jianhe Zhang ◽  
Liangfeng Wei ◽  
Xingfeng Qi ◽  
Yiming Ma ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Pituitary Adenomas ◽  
Glucose Transporter ◽  
Immunohistochemical Analysis ◽  
High Energy ◽  
Benign Tumors ◽  
Positive Staining ◽  
Cystic Change ◽  
Glucose Transporter 1 ◽  
Glut1 Expression

Tumor cells require large amounts of energy to sustain growth. Through the mediated transport of glucose transporters, the uptake and utilization of glucose by tumor cells are significantly enhanced in the hypoxic microenvironment. Pituitary adenomas are benign tumors with high-energy metabolisms. We aimed to investigate the role of expression of glucose transporter 3 (GLUT3) and glucose transporter 1 (GLUT1) in pituitary adenomas, including effects on size, cystic change and hormone type. Pituitary adenomas from 203 patients were collected from January 2013 to April 2017, and immunohistochemical analysis was used to detect the expression of GLUT3 and GLUT1 in tumor specimens. GLUT3-positive expression in the cystic change group was higher than that in the non-cystic change group (P = 0.018). Proportions of GLUT3-positive staining of microadenomas, macroadenomas, and giant adenomas were 22.7 (5/22), 50.4 (66/131) and 54.0% (27/50), respectively (P = 0.022). In cases of prolactin adenoma, GLUT3-positive staining was predominant in cell membranes (P = 0.000006), while in cases of follicle-stimulating hormone or luteotropic hormone adenoma, we found mainly paranuclear dot-like GLUT3 staining (P = 0.025). In other hormonal adenomas, GLUT3 was only partially expressed, and the intensity of cell membrane or paranuclear punctate staining was weak. In contrast to GLUT3, GLUT1 expression was not associated with pituitary adenomas. Thus, our results indicate that the expression of GLUT3 in pituitary adenomas is closely related to cystic change and hormonal type. This study is the first to report a unique paranuclear dot-like GLUT3 staining pattern in pituitary adenomas.

Sign in / Sign up

Export Citation Format

Share Document